A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503803-27-00

Acronym

PCI-32765CAN3001

Enrollment

137

Registered

2023-10-24

Start date

2013-10-25

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-cell non-Hodgkin's lymphoma and cGVHD

Brief summary

Number of participants affected by an adverse event

Detailed description

Number of participants with change in disease status

Interventions

DRUGIbrutinib - capsule - 140 mg

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of participants affected by an adverse event	—

Secondary

Measure	Time frame
Number of participants with change in disease status	—

Countries

Belgium, France, Germany, Greece, Italy, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026